Mitochondrial aldehyde dehydrogenase, a potential drug target for protection of heart and brain from ischemia/reperfusion injury

Current Drug Targets

Volumn 15, Issue 10, 2014, Pages 948-955

  Luo, Xiu Ju ^a   Liu, Bin ^a   Ma, Qi Lin ^a,b   Peng, Jun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

4 hydroxy 2 nonenal (4 HNE); Alda 1; Aldehyde; Ischemia reperfusion injury; Mitochondrial aldehyde dehydrogenase (ALDH2); Oxidative stress

Indexed keywords

3, 4 METHYLENEDIOXYAMPHETAMINE; 4 HYDROXYNONENAL; ALDA 44; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BENOMYL; CHLORPROPAMIDE; DAIDZIN; ENZYME ACTIVATOR; GLYCERYL TRINITRATE; N (1,3 BENZODIOXOL 5 YL METHYL) 2,6 DICHLOROBENZAMIDE; PROTEIN KINASE C; THIOCTIC ACID; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; ALDH2 PROTEIN, HUMAN; ENZYME INHIBITOR;

ACUTE CORONARY SYNDROME; ALCOHOL METABOLISM; ALDEHYDE DEHYDROGENASE BRIGHT CELL; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; ENZYME ACTIVITY; HEART DISEASE; HEART PROTECTION; HUMAN; ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN EXPRESSION; REPERFUSION INJURY; STEM CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; MYOCARDIAL REPERFUSION INJURY;

ALDEHYDE DEHYDROGENASE; ANIMALS; BRAIN ISCHEMIA; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; MYOCARDIAL REPERFUSION INJURY; REPERFUSION INJURY;

EID: 84916220775     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Roth C, Reith W, Walter S, et al. Mechanical recanalization with flow restoration in acute ischemic stroke: the ReFlow (mechanical recanalization with flow restoration in acute ischemic stroke) study. JACC Cardiovasc Interv 2013; 6(4): 386-91.
2. Choi D, Hwang KC, Lee KY, Kim YH. Ischemic heart diseases: current treatments and future. J Control Release 2009; 140(3): 194-202.
3. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology 2007; 49(2): 93-102.
4. Fauconnier J, Roberge S, Saint N, Lacampagne A. Type 2 ryanodine receptor: a novel therapeutic target in myocardial ischemia/reperfusion. Pharmacol Ther 2013; 138(3): 323-32.
5. Zhang YS, He L, Liu B, et al. A novel pathway of NADPH oxidase/vascular peroxidase 1 in mediating oxidative injury following ischemia-reperfusion. Basic Res Cardiol 2012; 107(3): 266.
6. Chen H, Yoshioka H, Kim GS, et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 2011; 14(8): 1505-17.
7. Zheng R, Po I, Mishin V, et al. The generation of 4-hydroxynonenal, an electrophilic lipid peroxidation end product, in rabbit cornea organ cultures treated with UVB light and nitrogen mustard. Toxicol Appl Pharmacol 2013; 272(2): 345-55.
8. Nam TG. Lipid Peroxidation and Its Toxicological Implications. Toxicol Res 2011; 27(1): 1-6.
9. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008; 321(5895): 1493-5.
10. Suda S, Katsura K, Kanamaru T, Saito M, Katayama Y. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur J Pharmacol 2013; 707(1-3): 26-31.
11. Zhang P, Xu D, Wang S, et al. Inhibition of aldehyde dehydrogenase 2 activity enhances antimycin-induced rat cardiomyocytes apoptosis through activation of MAPK signaling pathway. Biomed Pharmacother 2011; 65(8): 590-3.
12. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 2012; 52(4): 735-46.
13. Koppaka V, Thompson DC, Chen Y, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012; 64(3): 520-39.
14. He L, Liu B, Dai Z, et al. Alpha lipoic acid protects heart against myocardial ischemia-reperfusion injury through a mechanism involving aldehyde dehydrogenase 2 activation. Eur J Pharmacol 2012; 678(1-3): 32-8.
15. Fu SH, Zhang HF, Yang ZB, et al. Alda-1 reduces cerebral ischemia/reperfusion injury in rat through clearance of reactive aldehydes. Naunyn Schmiedebergs Arch Pharmacol 2014; 387(1): 87-94.
16. Perin EC, Silva GV, Zheng Y, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163(3): 415-21, 21 e1.
17. Singh S, Brocker C, Koppaka V, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 2013; 56: 89-101.
18. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004; 63(1): 49-63.
19. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008; 4(6): 697-720.
20. Scott DM, Taylor RE. Health-related effects of genetic variations of alcohol-metabolizing enzymes in African Americans. Alcohol Res Health 2007; 30(1): 18-21.
21. Yokoyama M, Yokoyama A, Yokoyama T, et al. Hangover susceptibility in relation to aldehyde dehydrogenase-2 genotype, alcohol flushing, and mean corpuscular volume in Japanese workers. Alcohol Clin Exp Res 2005; 29(7): 1165-71.
22. Jung JG, Kim JS, Oh MK. The role of the flushing response in the relationship between alcohol consumption and insulin resistance. Alcohol Clin Exp Res 2010; 34(10): 1699-704.
23. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 2010; 88(1): 51-7.
24. Beretta M, Gorren AC, Wenzl MV, et al. Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1. J Biol Chem 2010; 285(2): 943-52.
25. Larson HN, Zhou J, Chen Z, Stamler JS, Weiner H, Hurley TD. Structural and functional consequences of coenzyme binding to the inactive asian variant of mitochondrial aldehyde dehydrogenase: roles of residues 475 and 487. J Biol Chem 2007; 282(17): 12940-50.
26. Guo R, Chen XP, Guo X, et al. Evidence for involvement of calcitonin gene-related peptide in nitroglycerin response and association with mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism. J Am Coll Cardiol 2008; 52(11): 953-60.
27. Hink U, Daiber A, Kayhan N, et al. Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol 2007; 50(23): 2226-32.
28. Zhang XJ, Chang L, Zhang YM, Deng S, Li YJ, Peng J. Comparing the role of glutathione-S-transferase and mitochondrial aldehyde dehydrogenase in nitroglycerin biotransformation and the correlation with calcitonin gene-related peptide. Eur J Pharmacol 2009; 617(1-3): 97-101.
29. DiFabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 2003; 64(5): 1109-16.
30. Povsic TJ, Zavodni KL, Kelly FL, et al. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol 2007; 50(23): 2243-8.
31. Balber AE. Concise review: aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011; 29(4): 570-5.
32. Gentry T, Foster S, Winstead L, Deibert E, Fiordalisi M, Balber A. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy 2007; 9(3): 259-74.
33. White HS, Smith L, Gentry T, Balber AE. Mechanisms of action of human aldehyde dehydrogenase bright bells in therapy of cardiovascular diseases: expression analysis of angiogenic factors and aldehyde dehydrogenase isozymes. J Stem Cell Res Ther 2011; S1: 1-9.
34. Ma H, Guo R, Yu L, Zhang Y, Ren J. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur Heart J 2011; 32(8): 1025-38.
35. Ping P. Getting to the heart of proteomics. N Engl J Med 2009; 360(5): 532-4.
36. Robador PA, Seyedi N, Chan NY, Koda K, Levi R. Aldehyde dehydrogenase type 2 activation by adenosine and histamine inhibits ischemic norepinephrine release in cardiac sympathetic neurons: mediation by protein kinase Cepsilon. J Pharmacol Exp Ther 2012; 343(1): 97-105.
37. Koda K, Salazar-Rodriguez M, Corti F, et al. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation 2010; 122(8): 771-81.
38. Gu C, Xing Y, Jiang L, et al. Impaired Cardiac SIRT1 Activity by Carbonyl Stress Contributes to Aging-Related Ischemic Intolerance. PLoS One 2013; 8(9): e74050.
39. Sondergaard CS, Hess DA, Maxwell DJ, et al. Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. J Transl Med 2010; 8: 24.
40. Russo J, Barnes A, Berger K, et al. 4-(N, Ndipropylamino) benzaldehyde inhibits the oxidation of all-trans retinal to all-trans retinoic acid by ALDH1A1, but not the differentiation of HL-60 promyelocytic leukemia cells exposed to all-trans retinal. BMC Pharmacol 2002; 2: 4.
41. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009; 111(6): 483-95.
42. Lee WC, Wong HY, Chai YY, et al. Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochem Biophys Res Commun 2012; 425(4): 842-7.
43. Guo JM, Liu AJ, Zang P, et al. ALDH2 protects against stroke by clearing 4-HNE. Cell Res 2013; 23(7): 915-30.
44. Perez-Miller S, Younus H, Vanam R, Chen CH, Mochly-Rosen D, Hurley TD. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat Struct Mol Biol 2010; 17(2): 159-64.
45. Budas GR, Disatnik MH, Chen CH, Mochly-Rosen D. Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCvarepsilon) knockout mice. J Mol Cell Cardiol 2010; 48(4): 757-64.
46. Lang XE, Wang X, Zhang KR, Lv JY, Jin JH, Li QS. Isoflurane preconditioning confers cardioprotection by activation of ALDH2. PLoS One 2013; 8(2): e52469.
47. Padmalayam I. Targeting mitochondrial oxidative stress through lipoic acid synthase: a novel strategy to manage diabetic cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2012; 10(3): 223-33.
48. Wenzel P, Hink U, Oelze M, et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 2007; 282(1): 792-9.
49. Dudek M, Bednarski M, Bilska A, et al. The role of lipoic acid in prevention of nitroglycerin tolerance. Eur J Pharmacol 2008; 591(1-3): 203-10.
50. Li RJ, Ji WQ, Pang JJ, Wang JL, Chen YG, Zhang Y. Alpha-lipoic acid ameliorates oxidative stress by increasing aldehyde dehydrogenase-2 activity in patients with acute coronary syndrome. Tohoku J Exp Med 2013; 229(1): 45-51.
51. Keung WM. Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence. Med Res Rev 2003; 23(6): 669-96.
52. Lowe ED, Gao GY, Johnson LN, Keung WM. Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem 2008; 51(15): 4482-7.
53. Arolfo MP, Overstreet DH, Yao L, et al. Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcohol Clin Exp Res 2009; 33(11): 1935-44.
54. Staub RE, Quistad GB, Casida JE. Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice. Chem Res Toxicol 1998; 11(5): 535-43.
55. Bakare-Odunola MT, Mustapha A, Abdu Aguye I. Effect of Nigerian meals on the pharmacokinetics of chlorpropamide in type II diabetic patients. Eur J Drug Metab Pharmacokinet 2008; 33(1): 31-5.
56. Suzuki Y, Taniyama M, Muramatsu T, et al. ALDH2/ADH2 polymorphism associated with vasculopathy and neuropathy in type 2 diabetes. Alcohol Clin Exp Res 2004; 28(8 Suppl Proceedings): 111S-6S.
57. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008; 9(7): 541-53.